TY - JOUR
T1 - Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
AU - Omer, Bilal
AU - Kadan-Lottick, Nina S.
AU - Roberts, Kenneth B.
AU - Wang, Rong
AU - Demsky, Carolyn
AU - Kupfer, Gary M.
AU - Cooper, Dennis
AU - Seropian, Stuart
AU - Ma, Xiaomei
PY - 2012/9
Y1 - 2012/9
N2 - To evaluate the impact of reduced radiation and combined modality therapy (CMT) in the treatment of Hodgkin lymphoma, we assessed the risk of second malignant neoplasms (SMNs) in patients who received extended-field radiotherapy only and patients who underwent CMT. Among 404 patients treated at Yale during 1970-2004, the risk of solid SMNs was elevated in the radiotherapy only group (n = 198, median follow-up = 21·1 years) compared to the general population, with a standardized incidence ratio (SIR) of 1·85 [95% confidence interval (CI): 1·17-2·78]. No increase was observed in the CMT group (n = 206, median follow-up = 14·3 years), although potential differences in SMN risk were indicated across the age spectrum in subgroup analysis. Patients who received mustard-containing regimens had increased risks for haematological SMNs (SIR = 8·74) and all SMNs (SIR = 1·85). When the analysis was stratified by age at diagnosis, children (0-20 years) had a significantly higher risk of SMNs (SIR = 5·24, 95% CI: 2·26-10·33), regardless of the treatment received. These findings suggest that recent treatment options utilizing lower dose radiation and less intense alkylator chemotherapy might be associated with lower incidences of SMNs among adults but not necessarily children.
AB - To evaluate the impact of reduced radiation and combined modality therapy (CMT) in the treatment of Hodgkin lymphoma, we assessed the risk of second malignant neoplasms (SMNs) in patients who received extended-field radiotherapy only and patients who underwent CMT. Among 404 patients treated at Yale during 1970-2004, the risk of solid SMNs was elevated in the radiotherapy only group (n = 198, median follow-up = 21·1 years) compared to the general population, with a standardized incidence ratio (SIR) of 1·85 [95% confidence interval (CI): 1·17-2·78]. No increase was observed in the CMT group (n = 206, median follow-up = 14·3 years), although potential differences in SMN risk were indicated across the age spectrum in subgroup analysis. Patients who received mustard-containing regimens had increased risks for haematological SMNs (SIR = 8·74) and all SMNs (SIR = 1·85). When the analysis was stratified by age at diagnosis, children (0-20 years) had a significantly higher risk of SMNs (SIR = 5·24, 95% CI: 2·26-10·33), regardless of the treatment received. These findings suggest that recent treatment options utilizing lower dose radiation and less intense alkylator chemotherapy might be associated with lower incidences of SMNs among adults but not necessarily children.
KW - Chemotherapy
KW - Combined modality therapy
KW - Hodgkin
KW - Lymphoma
KW - Radiotherapy
KW - Second malignant neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84865148841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865148841&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2012.09211.x
DO - 10.1111/j.1365-2141.2012.09211.x
M3 - Article
C2 - 22775513
AN - SCOPUS:84865148841
SN - 0007-1048
VL - 158
SP - 615
EP - 625
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -